ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novartis, Shenzhen Salubris Pharmaceuticals and Viatris side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Novartis×Shenzhen Salubris Pharmaceuticals×Viatris×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovartisShenzhen Salubris PharmaceuticalsViatris
studies on the registry3,90250778
open to participants now212209
phase 3 studies under way9406
reach primary completion within a year12898
programswith a study of their own in two years77+7 named only206

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovartisShenzhen Salubris PharmaceuticalsViatris
Phase 1

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%

Shenzhen Salubris Pharmaceuticals: 7 of its 20 programs at phase 1

  1. Once Daily (QD), Multiple Ascending Dose (MAD)phase 1
  2. Reference Groupphase 1
  3. SAL0123phase 1
  4. SAL0133phase 1
  5. Sequence A T-R-T-Rphase 1

and 2 more — sign in to see them all

35%
00%
Phase 2

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. DDY391phase 2
  4. arumakimigphase 2
  5. QCZ484phase 2

and 30 more — sign in to see them all

45%

Shenzhen Salubris Pharmaceuticals: 6 of its 20 programs at phase 2

  1. SAL0140phase 2
  2. GW906phase 2
  3. SAL0167phase 2
  4. JK07phase 2
  5. SAL0137phase 2

and 1 more — sign in to see them all

30%

Viatris: 1 of its 6 programs at phase 2

  1. MR-130A-01phase 2
17%
Phase 3

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%

Shenzhen Salubris Pharmaceuticals: 6 of its 20 programs at phase 3

  1. SAL-0951phase 3
  2. SAL0120phase 3
  3. SAL056phase 3
  4. SAL003phase 3
  5. SAL067phase 3

and 1 more — sign in to see them all

30%

Viatris: 2 of its 6 programs at phase 3

  1. cenerimodphase 3
  2. selatogrelphase 3
33%
Approved, new studies

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Shenzhen Salubris Pharmaceuticals: 1 of its 20 programs at approved, new studies

  1. enarodustatapproved, new study
5%

Viatris: 3 of its 6 programs at approved, new studies

  1. Gabapentinapproved, new study
  2. Alprazolamapproved, new study
  3. Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionateapproved, new study
50%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
Shenzhen Salubris Pharmaceuticals5 readouts · 1 phase 3·

Shenzhen Salubris Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. SAL0137phase 2 · Dec 12 · NCT07729475
··

Shenzhen Salubris Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion

  1. SAL0140phase 2 · Mar 1 · NCT07654140
··

Shenzhen Salubris Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. enarodustatapproved, new study · Jun 0 · NCT07079579

Shenzhen Salubris Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion

  1. SAL0167phase 2 · Jul 30 · NCT07951411
··

Shenzhen Salubris Pharmaceuticals, Oct ’27: 1 program whose next study reaches primary completion

  1. GW906phase 2 · Oct 0 · NCT07835984
Viatris4 readouts · 3 phase 3

Viatris, Nov ’26: 1 program whose next study reaches primary completion

  1. MR-130A-01phase 2 · Nov 30 · NCT07365904

Viatris, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cenerimodphase 3 · Dec 31 · NCT05672576

Viatris, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Gabapentinapproved, new study · Jan 31 · NCT07813026
·····

Viatris, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. selatogrelphase 3 · Jul 0 · NCT04957719
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 6

  • remibrutinibphase 3 · terminated Nov 20“Sponsor decision based on pre-specified futility efficacy criteria being met.” · NCT06744920
  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Shenzhen Salubris Pharmaceuticals

New programs 2

  • SAL0150 dose 1phase 2 · first study · Nov 2 · Diabetes Mellitus, Type 2
  • GW906phase 2 · first study · Sep 17 · Hypertension

Reached a new phase 2

  • SAL0167phase 2 · Nov 16 · Hyperlipidemias
  • SAL0120phase 3 · Aug 24 · Hypertension

Study stopped 0

None

Primary completion later 0

None

Viatris

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionNovartisShenzhen Salubris PharmaceuticalsViatris
Myocardial Infarctionall three · compare here

Novartis in Myocardial Infarction: 1 program

  1. pacibekitugphase 3

Their studies: Novartis’s studies of Myocardial Infarction in search

Shenzhen Salubris Pharmaceuticals in Myocardial Infarction: 1 program

  1. sacubitrilphase 3

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Myocardial Infarction in search

Viatris in Myocardial Infarction: 1 program

  1. selatogrelphase 3

Their studies: Viatris’s studies of Myocardial Infarction in search

Hypertension2 of 3 · compare here

Novartis in Hypertension: 2 programs

  1. QCZ484phase 2
  2. HJB647phase 1

Their studies: Novartis’s studies of Hypertension in search

Shenzhen Salubris Pharmaceuticals in Hypertension: 3 programs

  1. SAL0120phase 3
  2. SAL0140phase 2
  3. GW906phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Hypertension in search

–
Renal Insufficiency, Chronic2 of 3 · compare here

Novartis in Renal Insufficiency, Chronic: 2 programs

  1. Atrasentanphase 3
  2. OJR520phase 1

Their studies: Novartis’s studies of Renal Insufficiency, Chronic in search

Shenzhen Salubris Pharmaceuticals in Renal Insufficiency, Chronic: 2 programs

  1. SAL0120phase 3
  2. SAL0140phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Renal Insufficiency, Chronic in search

–
Atherosclerosis2 of 3 · compare here

Novartis in Atherosclerosis: 2 programs

  1. pelacarsenphase 3
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Atherosclerosis in search

Shenzhen Salubris Pharmaceuticals in Atherosclerosis: 1 program

  1. SAL0137phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Atherosclerosis in search

–
Heart Failure2 of 3 · compare here

Novartis in Heart Failure: 1 program

  1. HJB647phase 1

Their studies: Novartis’s studies of Heart Failure in search

Shenzhen Salubris Pharmaceuticals in Heart Failure: 2 programs

  1. sacubitrilphase 3
  2. JK07phase 2

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Heart Failure in search

–
Hypercholesterolemia2 of 3 · compare here

Novartis in Hypercholesterolemia: 2 programs

  1. QCZ484phase 2
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Hypercholesterolemia in search

Shenzhen Salubris Pharmaceuticals in Hypercholesterolemia: 1 program

  1. SAL003phase 3

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Hypercholesterolemia in search

–
Lupus Erythematosus, Systemic2 of 3 · compare here–

Viatris in Lupus Erythematosus, Systemic: 1 program

  1. cenerimodphase 3

Their studies: Viatris’s studies of Lupus Erythematosus, Systemic in search

Lupus Nephritis2 of 3 · compare here

Novartis in Lupus Nephritis: 2 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Lupus Nephritis in search

–

Viatris in Lupus Nephritis: 1 program

  1. cenerimodphase 3

Their studies: Viatris’s studies of Lupus Nephritis in search

Renal Insufficiency2 of 3 · compare here

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

–

Viatris in Renal Insufficiency: 1 program

  1. cenerimodphase 3

Their studies: Viatris’s studies of Renal Insufficiency in search

Chagas Disease2 of 3 · compare here

Novartis in Chagas Disease: 1 program

  1. LXE408phase 2

Their studies: Novartis’s studies of Chagas Disease in search

Shenzhen Salubris Pharmaceuticals in Chagas Disease: 1 program

  1. sacubitrilphase 3

Their studies: Shenzhen Salubris Pharmaceuticals’ studies of Chagas Disease in search

–
Coronary Artery Disease2 of 3 · compare here

Novartis in Coronary Artery Disease: 1 program

  1. YMI024phase 2

Their studies: Novartis’s studies of Coronary Artery Disease in search

–

Viatris in Coronary Artery Disease: 1 program

  1. selatogrelphase 3

Their studies: Viatris’s studies of Coronary Artery Disease in search

Epilepsy2 of 3 · compare here

Novartis in Epilepsy: 1 program

  1. Phenytoinphase 1

Their studies: Novartis’s studies of Epilepsy in search

–

Viatris in Epilepsy: 1 program

  1. Alprazolamapproved, new study

Their studies: Viatris’s studies of Epilepsy in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetNovartisShenzhen Salubris PharmaceuticalsViatris
PCSK9inclisiranruleSAL003rule–
A target, or a pathogen for a vaccine, known for: Novartis 56 of 77 · Shenzhen Salubris Pharmaceuticals 4 of 20 · Viatris 4 of 6 programs (24 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).